ALLOGENE THERAPEUTICS

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

11 May 2023 10:50:32 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

03 May 2023 15:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

26 Apr 2023 09:06:38 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023

25 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

20 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

17 Apr 2023 09:15:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

13 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

30 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

14 Mar 2023 16:30:48 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

02 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy 

01 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 Feb 2023 15:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

21 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology

01 Feb 2023 13:55:08 By Nasdaq GlobeNewswire

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

25 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

24 Jan 2023 07:30:16 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

17 Jan 2023 15:05:24 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development

03 Jan 2023 07:00:02 By Nasdaq GlobeNewswire

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

29 Nov 2022 14:30:12 By Nasdaq GlobeNewswire